Pharm exam 1: section 3 Flashcards
Anticoagulation
Indications
Venous thromboembolism: prevention and tx Stroke prevention in setting of afib Ischemic stroke Prosthetic cardiac valve Coronary and PVD Hypercoagulable disease
Prophylaxis for clotting events in high risk pt that might have high risk procedure
Warfarin
Vitamin K antagonist
Inhibits synthesis of Vitamin K dependent clotting factors: X IX VII (half life = 6 hrs) II (prothrombin) (half like 60 hours) Coagulation inhibitor proteins C, Z, S Average half life 36-42 hrs (3-4 days) Onset: depends on time needed to deplete factors
Warfarin
Pharmacokinetics
Well absorbed PO
Metabolized by enzymes CYP1A2 & CYP2CP
Precautions and C/I
- Pregnancy category X
- Cautious use in pt w/ fall risk, dementia, or uncontrolled HTN
- avoid: recent hemorrhagic stroke, active bleeding, recent trauma/surgery, presence of spinal catheter, aneurysm, CNS tumor
Warfarin
Adverse reactions
Bleeding
-antidote is vitamin K
Allergic reactions
Drug interactions
- simvastatin, fish oil, garlic, prednisone may increase INR
- Phenytoin and phenobarbital may decrease INR
- decreased by foods w/ vitamin K
Warfarin
* never initiated at mono therapy bc takes a long time for warfarin to reach full therapeutic effect
Clinical Dosing Start @ 5mg/day (7.5mg/day if weight > 80 kg) Consider lower dose if: > 75 yo Multiple cormorbidities Elevated liver enzymes Changing thyroid status
INR hows prolongation w/in 3 days after starting d/t rapid depletion of factor VII
Full anticoagulation after depletion of factor II depleted (2-14 days)
Check daily until in range on 2 consecutive days
Check 2x weekly for 1-2 weeks
Then less frequently (@ least every 6 weeks)
Warfarin
Target INR
INR 2-3 VTE DVT stroke prevention in afib valves hypercoagulable condition
INR 2.5- 3.5
Heart valvle
hypercoagulable condition
Direct acting Oral anticoagulants
Dabigatran (Pradaxa)
Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug
Few drug interactions
Renal clearance
Half life: 14-17hrs
Avoid in pt w/:
CrCl <15 ml/min
dialysis
prosthetic heart valve
Adverse reactions
bleeding (administer fresh frozen plasma)
GI vs intracranial bleeding
GI effects
Drug -drug interactions
- quinidine: increase levels by 100%
- amiodarone: increase levels by 50%
- rifampin: may decrease effects
- PPIs and antacids - separate doses by 2 hrs
Dosing: reduce risk of CVA in pt w/ afib
150mg BID - normal renal function
75mg BID - decreased renal function
Check hepatic function at baseline and periodically if concern
Cannot crush
Cannot be put in pill box bc its packaged in moisture proof container
Direct acting oral anticoagulants
Rivaroxaban (Xarelto)
PE tx
DVT prevention
Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug
Few drug interactions
Renal clearance
Half life: 14-17hrs
Avoid in pts w/ heart valve
Avoid in CrCl < 30ml/min
must be taken with food to improve bioavailability
Direct acting oral anticoagulants
Apixaban (Eliquis)
Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug
Few drug interactions
Renal clearance
Half life: 14-17hrs
Least dependence on CrCl
good for pts w/ kidney function issues
Direct acting oral anticoagulants
Edoxaban( Savaysa)
Less drug-drug interactions
Cannot use in CrCl: >95ml/min -> cause stroke
Direct acting Oral anticoagulants
Indications
DVT and PE treatment
DVT prevention
stroke
Bind to factor Xa: Block thrombin
faster onset than warfarin; injectable bridge therapy not necessary as with warfarin
no dietary interactions
dosing adjustment not necessary
Direct acting oral anticoagulants
Transitioning
From warfarin:
start when INR at lower end of therapeutic range
From unfractionated heparin:
start when heparin is discontinued
From low molecular weight heparin (LMWH):
start when LMWH due next (usually 12 hrs from last dose)
Heparin
Binds w/ antithrombin III
inactivates factors IXa, Xa,XIIa, XIII
Given: IV or subQ (immediate action - emergency situations)
Not absorbed in GI
Extensively protein bound
Metabolized by liver / renal excretion
Caution in Pregnancy; category C
Avoid in advanced hepatic or renal disease
Avoid in bleeding disorder or active bleeding
Heparin
Adverse reactions
HIT (immune response to heparin)
Life threatening bleeding
Pain at injection site, bruising: subQ
Antidote: protamine sulfate
Drug interactions
Cephalosporins and PCNs
warfarin, antiplatelets, thrombolytics
Valproic acid
Heparin
Dosing
Indications
Given 12 hrs pre-op
Maintenance q 8-12 hrs for 7 days post op
Monitor:
aptt
platelet and hematocrit q 2-3 days initially
Indications
acute thromboembolism
VTE prophylaxis
LMWH
Fragments of unfrationated heparin
Inactivates thrombin and factor Xa
No lab monitoring
Fixed dosing at prophylaxis: aptt may not be significantly prolonged at prophylaxis doses
Weight based with therapeutic dosing: At therapeutic doses aptt prolongation not used to measure therapeutic effect
Half life: 108-252 minute
LMWH
Enoxaparin
DVT or PE
Pre-op given 12 hrs before surgey
Still at risk for HIIT
LMWH
Fondaparinux
DVT
Hip fracture surgery or knee replacement
Risk for HIIT is subsequently lower